SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-22-065317
Filing Date
2022-05-26
Accepted
2022-05-26 16:40:39
Documents
15
Period of Report
2022-05-26
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2216892d1_8k.htm   iXBRL 8-K 30961
2 EXHIBIT 3.1 tm2216892d1_ex3-1.htm EX-3.1 10122
3 EXHIBIT 99.1 tm2216892d1_ex99-1.htm EX-99.1 11522
7 GRAPHIC tm2216892d1_ex99-1img01.jpg GRAPHIC 15909
  Complete submission text file 0001104659-22-065317.txt   257976

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA casi-20220526.xsd EX-101.SCH 3033
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE casi-20220526_lab.xml EX-101.LAB 34476
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE casi-20220526_pre.xml EX-101.PRE 22595
9 EXTRACTED XBRL INSTANCE DOCUMENT tm2216892d1_8k_htm.xml XML 3703
Mailing Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850
Business Address 9620 MEDICAL CENTER DR STE 300 ROCKVILLE MD 20850 240-864-2600
CASI Pharmaceuticals, Inc. (Filer) CIK: 0000895051 (see all company filings)

IRS No.: 581959440 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-20713 | Film No.: 22970784
SIC: 2836 Biological Products, (No Diagnostic Substances)